Sermo Report Indicates That Ticagrelor Is Likely To Affect The Standard Of Care For A

tD33NAt

Active member
Sermo, the world's largest online community for physicians, announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome (ACS). According to the results, 46% of physicians feel that ticagrelor will likely affect the current standard of care, Plavix (clopidogrel), for ACS patients. If approved, 57% of physicians said they could switch up to 20% of their patients to ticagrelor...


Zoe0gD6l8bI


More...
 
Top